GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (FRA:6K9) » Definitions » Additional Paid-In Capital

Context Therapeutics (FRA:6K9) Additional Paid-In Capital : €73.74 Mil(As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Additional Paid-In Capital?


Context Therapeutics's quarterly additional paid-in capital declined from Sep. 2023 (€74.64 Mil) to Dec. 2023 (€73.28 Mil) but then increased from Dec. 2023 (€73.28 Mil) to Mar. 2024 (€73.74 Mil).

Context Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€68.60 Mil) to Dec. 2022 (€74.42 Mil) but then declined from Dec. 2022 (€74.42 Mil) to Dec. 2023 (€73.28 Mil).


Context Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Context Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics Additional Paid-In Capital Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
1.33 1.54 68.60 74.42 73.28

Context Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.89 73.29 74.64 73.28 73.74

Context Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Context Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Context Therapeutics (FRA:6K9) Business Description

Traded in Other Exchanges
Address
2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Context Therapeutics (FRA:6K9) Headlines

No Headlines